Navigation Links
Brigham and Women's Hospital awarded $9.6 million to study whole genome sequencing
Date:12/8/2011

Boston, MA Brigham and Women's Hospital (BWH) has been awarded $9.6 million over four years from the National Human Genome Research Institute (NHGRI) to fund the Medical Sequencing (MedSeq) Research Project. The MedSeq Project is the first clinical trial ever funded by NIH to empirically study the use of whole genome sequencing, the mapping of an individuals' entire DNA, in the practice of medicine.

The proposed project, led by a multi-disciplinary team of more than 40 scientists, will first design an informatics pipeline to interpret several million genetic variants from each patient, and generate clinical reports that will be meaningful to practicing physicians. After that, 200 patients and their physicians will be enrolled in a clinical trial where they will receive either standard care with whole genome sequencing or standard care without whole genome sequencing. Researchers will study two types of volunteers healthy middle-aged patients followed by primary care physicians and patients with newly diagnosed hereditary cardiomyopathy. The MedSeq Project will begin enrollment in 2012.

"This study will build on the expertise and accomplishments of this remarkable scientific team to create and test novel methods for interpreting whole genome sequencing information and actually using that information in clinical medicine," said Robert C. Green, MD, MPH, a physician-scientist in the Division of Genetics at BWH and overall director of the study. "This research will accelerate the use of genomics in clinical care, taking another step toward fulfilling the promise that genome sciences will usher in an era of personalized genetic medicine for the betterment of human health."

The first human genome was decoded through the Human Genome Project in 2003, however the use of individual sequencing in medical care is only beginning now, largely due to the falling costs of sequencing and bioinformatics advances. The MedSeq Project is the first clinical trial funded by NIH to support translating complicated genomic sequence data into understandable laboratory reports, and to evaluate how these reports will be used in a clinical setting.

"One of the most controversial issues the study team will face is whether to look for and whether to report 'incidental' genetic findings or mutations that suggest previously unsuspected genetic predisposition to cancer, heart disease or other conditions that are found in otherwise healthy individuals," Green said. "Reporting too many incidental results could generate unnecessary and costly medical tests, while reporting too few could deprive patients and doctors of valuable risk information."

In addition to Green, the research will be led by co-directors Mike Murray, MD, Christine Seidman, MD and Heidi Rehm, PhD from Brigham and Women's Hospital. As well as Amy McGuire, JD, PhD from Baylor College of Medicine and Zak Kohane, MD, PhD, from Children's Hospital Boston.

Speaking to the significance of the study, Kohane said, "medical practice and medical education by and large does not currently address the procedures and challenges of disclosing large-scale genomic data to patients. This grant will allow us to determine what part of the process needs refinement, where additional education of either the patient of physician will make for a more productive encounter, and how best to summarize this vast body of data in one all-to-brief clinical encounter."


'/>"/>

Contact: Tom Langford
tlangford@partners.org
617-534-1605
Brigham and Women's Hospital
Source:Eurekalert

Related biology news :

1. NIH awards $17 million Program of Excellence Award in glycosciences to Brigham and Womens Hospital
2. Brigham and Womens Hospital researcher named National Space Biomedical Research Institute Fellow
3. University Hospitals Seidman Cancer Center tests novel drug that makes brain tumors glow hot pink
4. University Hospitals Case Medical Center unlocks mystery of dystonia with advanced imaging
5. BUSM: Severe sepsis, new-onset AF associated with increased risk of hospital stroke, death
6. Childrens Hospital of Philadelphia and BGI announce partnership and new Joint Genome Center
7. The Childrens Hospital of Philadelphia and BGI Announce Partnership and New Joint Genome Center to Target Pediatric Diseases
8. Study: Residential washers may not kill hospital-acquired bacteria
9. Researchers at Cruces Hospital describe new syndrome of slight family intellectual disability
10. Thomas Jefferson University Hospital adopts new automated laboratory
11. Mass. Eye and Ear awarded largest NIH grant in hospital’s history
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
(Date:11/19/2016)... 18, 2016 Securus Technologies, a leading provider ... safety, investigation, corrections and monitoring, announced today that it ... to have an independent technology judge determine who has ... high tech/sophisticated telephone calling platform, and the best customer ... do most of what we do – which clearly ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... -- According to the new market ... Instruments, Automated Cell Expansion System), Cells Types (Human, ... Cancer, and Cell-Based Research), End-users (Biopharmaceutical and Biotechnology ... Trends, Growth, Share, Size and Forecast to 2022", ... expansion market is expected to reach USD 18.74 ...
(Date:12/5/2016)... Mich. , Dec. 5, 2016 NxGen MDx announced today ... bringing the test in house, we,ve been able to improve customer service ... for patients," says Alan Mack , CEO of NxGen MDx. ... , , ... test volume has led to more job opportunities at the Grand Rapid ...
(Date:12/5/2016)... -- The U.S. Biotechnology industry is the ... revenue and some $890 billion of total market value. In ... and this figure is expected to exceed $220 billion ... four equities for assessment: Northwest Biotherapeutics Inc. (NASDAQ: ... ACAD ), Acorda Therapeutics Inc. (NASDAQ: ACOR ...
(Date:12/4/2016)...  In five studies being presented today during the ... Exposition in San Diego , researchers ... delivery of life-saving treatments to patients with a variety ... carry therapies directly to the sites in the body ... substantial advantage over traditional, systemic methods. The studies highlight ...
Breaking Biology Technology: